

- 1) **Abdel-Rahman, H.M.; El Sahly, A.M; Khalafallah, W.E. and Anwar, R. (1980):** Problem of Schistosomiasis in Nile Delta. J. Egypt. Med. Assoc., **63**,135.
- 2) **Abdel-Rahman, H.M.; Hassan M.M.; El Sahly, A.M. and Abul Fadl, M.A.M. (1984):** Serum enzymatic activity in schistosomiasis. J. Egypt. Med. Assoc., **61**: 395-403.
- 3) **Abdel - Wahab, M.F. (1982) :** Schistosomiasis in Egypt, Boca Raton, USA. CRC Press Inc., Florida P:171.
- 4) **Abramowicz, M. (1992):** Drugs for parasitic infections. Medical letter, **34**: 17-26
- 5) **Ali, M.Q.; Doebling, E.S.; Abdel-Rahim, I.M.; Schlake, J.;Kardorff,R.;Franke,D.andKaiser,C.(1991):**Ultrasono graphical investigation of periportal fibrosis in children with S.mansoni infection: reversibility of morbidity seven months after treatment with praziquantel. Am. J. Trop. Med. Hyg., **44(4)**: 444-451 .
- 6) **Anderson, R.M. and May, R.M. (1982):** Population dynamics of human helminth infections : control by chemotherapy. Nature, **297**: 557-563.
- 7) **Anderson, R.M. and May, R.M. (1985):** Helminth infections of humans : mathematical models, population dynamics and control ,Adv. Parasitol., **24**: 1-101.

- 8) **Anderson, R.M. and Medley, G.F. (1985):** Community control of helminth infections of man by mass and selective chemotherapy. *Parasitology*, **90**: 629-660.
- 9) **Anderson, R.M. (1987):** Determinants of infection in human schistosomiasis. In: Mahmoud A.A.F. (ed.) *Schistosomiasis, Bailliere's Clin. Trop. Med. Comm. Dis.*, **2**: 279-300.
- 10) **Andrade, Z.A. and deBrito, P.A. (1982):** Curative chemotherapy and resistance to reinfection in murine schistosomiasis. *Am. J. Trop. Med. Hyg.*, **31**: 116-121.
- 11) **Andrade A.A. and Grimaud J.A. (1986):** Evaltion of the schistosomal hepatic lesions in mice after curative chemotherapy. *Am. J. Pathol.*, **124**: 59-65.
- 12) **Andrews, P. (1978) :** Effect of praziquantel on the free living stages of *S. mansoni*. *Z. Parasitnek.*, **56**: 99-106 .
- 13) **Andrews, P; Dycka J. and Frank, G. (1980):** Effect of pnaziquantel on clinical-chemical parameters in healthy and schistosome -infected mice. *Ann. Trop. Med. Parasitol.*, **71**:167-77.
- 14) **Andrews, P. (1981):** A summary of the efficacy of praziquantel against schistosomes in animal experiments and notes on its mode of action. *Arzneim. Forsch. Drug. Res.*, **31**: 538-541 .

- 15) **Andrews, P.; Thomas, H.; Pohlke, R. and Seubert, J. (1983):** Praziquantel. *Med. Res. Rev.*, **3**: 147-200 .
- 16) **Andrews, P. (1985):** Praziquantel, mechanism of anti - schistosomal activity. *Pharmacol. Ther.*, **29**:129-156.
- 17) **Aune, T.M.; Freeman G.L. and Colly, D.G. (1985):** Production of the lymphokine soluble immune suppressor (SIRS) during chronic experimental schistosomiasis mansoni. *J. Immunol.* **135**,2678 .
- 18) **Balkwill, F.R. and Burke. F. (1989):** The cytokine network. *Immunology Today*, **10**: 299-304 .
- 19) **Balkwill, R.R.; Moodie, E.M.; Freedman, V. and Fantes, K. (1989):** Human interferon inhibits the growth of established human breast tumors in nude mice. *Int. J. Cancer*, **30**:231-235.
- 20) **Barreto, M.L.; Silva, J.T.F.; Mott, K.E and Lelman, J.S. (1978):** Stability of faecal egg excretion in *S.mansoni* infection. *Trans. R. Soc. Trop. Med. Hyg.*, **72**:181-187 .
- 21) **Barreto, M.L. ; Smith, D.H. and Sleifh, A.C. (1990):** Implications of faecal egg count variations when using the Kato -Katz method to assess *S.mansoni* infections. *Trans. R. Soc. Trop. Med. Hyg.*, **84**:554-555 .
- 22) **Basham et al . (1983):** Predicta IFN- γ ELISA Kit technique. *J. Immunol.*, **130**:1492 .

- 23) **Becker, B.; Mehlhorn, H.; Andrews, P.; Thomas, H. and Eckert, J. (1980):** Light and electron microscopic studies on the effect of praziquantel on *S. mansoni*; *Dicrocoelium dendriticum* and *fasciola* in vitro. *Z. Parasitenk*, **63**:113-128 .
- 24) **Belosevic, M.; Finbloom, D.S.; Mettzen, M.S. and Nacy, C.A. (1990):** IL-2 a cofactor for induction of activated macrophage resistance to infection. *J Immunol.*, **145**:831.
- 25) **Bensasson, S.Z.; Legross, G-conrad, D.H.; Finkelman, F.D. and Paul, W.E. (1990):** IL-4 production by T- cells from naive donors : IL-2 is required for IL-4 production. *J Immunol.*, **145**:1127 .
- 26) **Bickle, Q.D. (1982):** Studies on the relationship between the survival of *S. mansoni* larvae in mice and the degree of resistance produced. *Parasitology*, **84**:111-123 .
- 27) **Billiau, A. (1988):** Interferon therapy pharmacokinetics and pharmacological aspects. *Arch. of Virology*, **67**:121-123 .
- 28) **Blair, K.L.; Bennet, J.L. and pax, R.A. (1992):** Praziquantel: physiological evidence of its sites of action in magnesium-paralysed *S. mansoni*. *Parasitol.*, **104**:59-66.
- 29) **Blalock et al. (1980):** Predicta IL-2 ELISA kit technique. *Cell Immunol.*, **49**:360 .

- 30) **Boros, D.L. (1978):** Granulomatous inflammation. *Prog Immunol*, **124**:183-267.
- 31) **Boros, D.L.(1986):** Immunoregulation of granuloma formation in murine schistosoma mansoni. *Ann. NY. Acad.Sci.*, **465**:313-323 .
- 32) **Boros, D.L. (1994):** The role of cytokines in the formation of the schistosome egg granuloma. *Immunobiol.*, **191(4-5)** : 441-50 .
- 33) **Botros S.S.; El- Badrawy ,N.; Metwally, A.A. and Khayyal, M.t . (1986):** Study of some immunopharmacological properties of praziquantel in experimental *S. mansoni*. *Ann. Trop. Med. Parasitol*; **80** :169-89 .
- 34) **Brindley, D.J.; Strand, M.; Norden, A.P. and Sher, A. (1989):** Role of host antibody in chemotherapeutic action of praziquantel against *S. mansoni*: identification of target antigens. *Molec. Biochem. Parasitol.*, **34**:99-108 .
- 35) **Brindley, P.J. and Sher, A. (1990):** Immunological involvement in the efficacy of praziquantel. *Experimental Parasitology*, **71**,245-248 .
- 36) **Brown, M.; Hu. L.J. and Paul, W.E. (1988):** IL-4/ B-cell stimulatory factor-1;stimulates T-cell growth by an IL-2 independent mechanism. *J. Immunol.*, **131**: 504 .

- 37) **Brown, M.A. and J.M. Hanifin (1990):** Atopic dermatitis. *Curropinions Immunol.*, 2:531 .
- 38) **Burstein.H.J.; Tepper,R.I.; Leder,P. and Abbas, A.K.(1991):** Humoral immune functions in IL-4 transgenic mice. *J. Immunol.*, 147 : 2950.
- 39) **Bushara, H. O.; Majid, B. Y. A.;Majid, A.A. et. al. (1983):** Observations on cattle schistosomiasis in Sudan, a study in comparative medicine. The effect of PZQ therpy on naturally acquired resistance to *S.bovis*. *Am. J. Trop. Med. Hyg.*, 32:1370-1374 .
- 40) **Butterworth, A.E.; Capron,M.; Cordingley, J.S.; Dalton, P.R.; Dunne, D.W.; Kariuki, H.C.; Kimani, G.; Koech, D.; Mugambi, M. ; Ouma, J. H.; Prentice, M.A.; Richardson, B.A.; Siongok, T.K.; Sturrock,R.F. and Taylor D.W.(1985) :** Immunity after treatment of human schistosomiasis mansoni.II. Identification of resistant individuals, and analysis of their immune responses. *Trans. R. Soc. Trop. Med. Hyg.*, 79 : 393-408.
- 41) **Butterworth, A.E. and Hagan, P. (1987) :** Immunity in human schistosomiasis. *Parasitol, Today*, 3 :11-16.
- 42) **Butterworth, A.E. (1987a) :** Potential for vaccines against human schistosomes. In Mohamed, A.A.F. (ed.), *Schisto-*

somiasis. *Bailliere's Clin. Trop. Med. Comm. Dis.*,2:465-483.

- 43) **Butterworth, A.E.; A.J.,Fulford;D.W., Dunne, J.H., Ouma and R.F., Sturrock (1988) :** Longitudinal studies on human schistosomiasis. *Philo. Trans. R. Soc. London Ser., B 321* : 495-511.
- 44) **Campbell, W.C. and Garcia, E.G.(1986) :** Trematode infections of man. In W.C., Campbell and R.S., *Rew. Chemotherapy of Parasitic Diseases*. Plenum Press, New York 385.
- 45) **Capron, A.;Dessaint, J.P.; Capron, M. et al. (1987):** Immunity to Schistosomes : Progress towards a vaccine. *Science*, 238: 1065-1072.
- 46) **Caulifield, J.p. and Chun-Pin, C. (1990) :** How does the schistosome evade host defenses. *Gastroenterology* , 98:1712-1713.
- 47) **Ceuppens et al. (1985) :** Predictor IL-2 ELISA kit technique. *J.Immunol.*, 129 : 2882.
- 48) **Cheever, A.W. (1968) :** A quantitative postmortem study of *S. mansoni* in man. *Am. J. Trop. Med. Hyg.*, 17:38-64.
- 49) **Cheever, A.W.; Macedonia, J.G.; Cheever, E.A. and Mosimann, J.E. (1992):** Persistence of eggs and hepatic

fibrosis after treatment of *S. mansoni* infected mice. *Am. J. Trop. Hyg*, **46**:752-758.

- 50) **Cheever, A.W.; Xu-Y ; Macedonia, J.G.; Cox, T.; Hieny, S. and Sher, A. (1992) :** The role of cytokines in the pathogenesis of hepatic granulomatous disease in *S.mansoni* infected mice. *Mem. Inst. Oswaldo. Cruz.*, **87** (suppl. 4) P 81 -85.
- 51) **Chensue, S.W.; Otterness, J.G.; Higashi, G.I. and Forch, C.S. (1989) :** Monokine production by hypersensitivity -*S.mansoni* egg and foreign body (Sephadex bead) type granuloma macrophages. *J. Immunol.*, **142**:1281-6.
- 52) **Chensue, S.W.; Warmington, K.S.; Ruth. J.; Lincoln, P.M. and Kunkel, S.L. (1994) :** Cross regulatory role of IFN- γ , IL-4 and IL-10 in schistosome egg granuloma formation, in vivo regulation of the activity and inflammation. *Clin Exp. Immunol.*, **98**(3) :395 - 400 .
- 53) **Chun - Pin, C. and Caulfield, J. (1989) :** Human lipoprotein binding to schistosomula of *S.mansoni*. *Am. J. Pathol.*, **135**:1015-1024.
- 54) **Clarke, G.M. and Cooke, D. (1994) :** A basic course in statistics. ELBS edition/Edward Arnold - Great Britain .
- 55) **Clegg, J.A. and Smithers, S.R. (1968) :** Death of schistosome cercariae during penetration of the Skin. II.

Penetration of mammalian skin by *S. mansoni*. *Parasitology* 85 : 111.

- 55) **Coffman, R.L.; Seymour, B.; Lebman, D.; Hirak, D. and Mosmann, T. (1988) :** The role of helper T-cell products in mouse B-cell differentiation and isotype regulation. *Immunol. Rev.*, **102** : 5-28.
- 56) **Conrad, D.H.; Bensasson, S.Z.; Le Gross, G.; Finkelman, F.D and Paul, W.El. (1990) :** Infection with *Nippostrongylus brasiliensis* or infection of anti-IgD antibodies markedly enhance FC-receptor-mediated IL-4 production by non B, non T-cells. *J. Exp. Med.*, **171** : 1997.
- 57) **Couissinier, Paris.P. and Dessein, A.J. (1995):** Schistosoma- specific helper T-cell clones from subjects resistant to infection by *S. mansoni* are: TH0/2. *Eur.J. Immunol.*, **25** (8) : 2295-302 .
- 58) **Cox, G.W.; Chattopadhyay, M.; Oppenheim , I.J.J. and Varesio, L. (1992) :** IL-4 inhibits the costimulatory activity of IL-2 or picolinic acid but not of lipopolysaccharide on IFN- γ treated macrophages *J. Immunol.*, **147**:3809.
- 59) **Davis, A. (1986):** Recent advances in schistosomiasis. *Q.J. Med.*, **58** : 95 - 110.

- 60) **Davis, B.D.; Dulbecco, R.; Eisen, H.N. and Ginsberg, H.S. (1990) :** Interferons : Effects, production after viral infection, relation to cells, chemical induction, characteristics of production, regulation of synthesis, mechanism of interferon action, protective role in viral infections and possible therapeutic use. *J. Microbiology*, **49**: 872 -877.
- 61) **Day,T.A.; Bennett,J.L. and Pax, R.A.(1992):** Praziquantel: the enigmatic antiparasitic. *Parasitol. Today*, **8(10)**: 342-344.
- 62) **Dean, D.A. and Mangold, B. L. (1992):** Evidence that both normal and immune elimination of *S.mansoni* take place at the lung stage of migration prior to parasite death. *Am. J. Trop. Med.*, **47**: 238 - 248 .
- 63) **Doehring-Schwerdtfeger,E.;Mohammed-Ali,G.; Abdel-Rahim,I.M.; Kardorff,R.; Franke,D.; Kaisec,C.; El-Sheikh,M. and Ehirsch,J.H.(1989):** Sonomorphological abnormalities in Sudanese children with *S.mansoni* infection : as proposed statging system for field diagnosis of periportal fibrosis. *Am. J. Trop. Med. Hyg.*; **41**: 63 - 9 .
- 64) **Doehring, S. ; Abdel Rahim , L.; Kardroff, R.; Kaiser, C. Frankc,D.; Richter, J., El-Sheikh,M. and Ali, Q.M. (1992):** Ultrasonographical investigation of periportal fibrosis in children with *S.mansoni* infecstion: reversibility

- of morbidity twenty three months after treatment with praziquantel. *Am. J. Trop. Med. Hyg.*, **46(4)**: 409-415.
- 65) **Doenhoff, M.; Bickle, Q.; Bain, J. et al. (1980)**: Factors affecting the acquisition of resistance against *S.mansoni* in mice. I. Demonstration of resistance to reinfection using a model system that involves perfusion of mice within three weeks of challenge. *J. Helminthol.*, **52**:173:186 .
- 66) **Doenhoff, M.J.; Sabah, A.A.; Fletcher, C.; Webbe, G. and Bain, G. (1987)**: Evidence of immune-dependent action of praziquantel on *S.mansoni* in mice. *Trans. R. Soc. Trop. Med. Hyg.*, **81**: 947-951.
- 67) **Due-Goiran, P.; Robert-Goillot, B.; Lopez, I. and Chany, C. (1985)**: Usual apparently constitutive interferons and antagonists, in human placental blood. *Proc. Natl. Acad. Sci. U.S.A.*, **82**:5010-5014 .
- 68) **El-Alamy, M.A. and Cline, B.L. (1977)**: Prevalance and intensity of *S.mansoni* and *S.haematobium* infection in Qualyub, Egypt. *Am. J. Trop. Med. Hyg.*, **26**: 470-478 .
- 69) **El-Badrawy, N.M.; Hassanein, H.I.; Botros S.S.; Nagy F.M.; Abdallah, N.M., and Herbage, D.(1988)**: Effect of praziquantel on hepatic fibrosis in experimental schistosomiasis mansoni. *Exp. Mol. Pathol.*, **49**:151-60 .

- 70) **El- Badrawy, N.M.; Abdel-Hadi, A.M.; Voss, B.I.; Metwally, A.A and Ebeid, F. (1991):** Effect of praziquantel on the distribution of intestinal collagen types I and III basement membrane, collagen types IV and V in murine hepatic schistosomiasis. *Trans. R. Soc. Trop. Med. Hyg.*, **85**: 752-755 .
- 71) **El-Gaddal, A.A. (1985):** The Blue Nile health project. A comprehensive approach to the prevention and control of water associated diseases in irrigated schemes of the Sudan. *J. Trop. Med. Hyg.*, **88**: 47-56.
- 72) **El- Hawey, A.; El-Rakaiby., A.; Shaker, M. and Naser, G. (1987):** Effect of praziquantel on hepatitis B virus markers distribution, in bilharzial and non- bilharzial school child. *J. Egypt. Med. Assoc.*, **70**:233-241 .
- 73) **El- Hawey, A.M.; Abdel-Aziz. T; El-Hak, S.; Massoud, A.M.; Rozeik, S. ; El- Darouty, A. and Hashim, Y.A (1990):** Study on liver profile after prolonged praziquantel courses for *S. mansoni* in Egyptian children on a field level. *J. Egypt. Soc. Parasitol.*, **20(2)**: 709-719 .
- 74) **Farrar and Schreiber (1993):** Predicta IL-2 ELISA kit technique. *Ann. Rev. Immunol.*, **11**:571 .
- 75) **Fernandez-Botzan, R.; Sanders, V.M. and Vitetta, E. SI. (1989):** Interactions between receptor for interleukin-2

and IL-4 on lines of helper T- cells (TH2) .

- 76) **Ford, M.J.; Q.D. Bickle and M.G.Taylor (1987):**
Immunity to *Schistosoma Mansoni* in congenitally athymic irradiated and mast cell-depleted rats. *Parasitology*, **94**: 313-326 .
- 77) **Freidman , R.M. (1990):** Interferons. Immunophysiology. Oxford University Press. New York, pp. 194-209 .
- 78) **Galizzi, J.P.; Zuber, C.E.; Cabrillat, H.; Djossous, O, and Banchereau, J . (1989):** Instedrnalization of human IL-4 and transient down-regulation of its receptor in the CD 23 inducible joye cells. *J. Biol. Chem.*, 264:6984 .
- 79) **Garovoy, M.R; Melzer. J.S.; Aschr, N.; Don Magilli - garn Jr. and Bozdech, M. (1991):** Clinical transplant - ation In stites DP and Terr AI (eds.) : Basic and Clinical Immunology. 7th edition. Appleton and Lange, London, Sydney, Toronto, Mexico, New Delhi. **60**, P:751 .
- 80) **Gastl, G.A.; Feldmeier, H.; Doebring, E.; Kortmann, C.;Daffalla, A.A. and Peter,H.H.(1984):**Numerical and functional alterations of lymphocytes in human schistosomiasis. *Scand. J. Immunol .*,**19**: 469 .
- 81) **Georgi, J.R.; Wade, S.E. and Dean, D.A. (1986):**
Attrition and temporal distribution of *S.mansoni* and

S. haematobium schistosomula in laboratory mice. Parasitology, **93**: 55: -70 .

- 82) Georgi, J.R. ; Wade, S.E. and Dean, D.A. (1987):** *S. mansoni*: mechanisms of attrition and routes of migration from lungs to hepatic portal system in the laboratory mice. J. Parasitol. **73**:706-711 .
- 83) Ghaffar, Y.; El-Ghazali, Y.; Abdel Salam, A.; Abdel Fattah, S. and Abdulla, I. (1988):** Effect of praziquantel therapy on liver functions in cases of schistosomiasis; associated with chronic active hepatitis. Afro-Arab liver journal , **1**:5-12 .
- 84) Gillis et al. (1982):** Predicta IL-2 ELISA kit technique Immunol. Rev. **63**:167 .
- 85) Goedel, D.V.; Yelverton, E.; Ulbrich, A.; Heyneker, H.L.; Miozzasi, G. et al. (1980):** Human leucocyte interferon produced by *E. coli* is biologically active. Nature: **287**:411-416 .
- 86) Goldsmith, R. (1991):** Pharmacology of antiparasitic drug. Drugs for the treatment of helminthic infections. Trop. Med. Parasitol., **83**:830-863 .
- 87) Goldsmith, R.S. (1992):** Clinical pharmacology of the antihelminthic drugs. In: Basic and Clinical Pharmacology,

5th edition, chapter 55, Katzung B.G. (ed.) Appleton and Lange, Norwalk, Connecticut.

- 88) **Gonnert, R. and Andrews, P. (1977):** Praziquantel, a new broad-spectrum antischistosomal agent. *Zeitschrift fur Parasitenkunde*, 52, 129-150 .
- 89) **Gray, P.W.; Leurg, D.W.; Pennica, D.; Yelverton, E.; Najarian, R. et al. (1982):** Expression of human immune interferon C DNA in E. coli and monkey cells. *Nature* : 295, 503-508 .
- 90) **Grimm et al (1983):** Predicta IL-2 ELISA kit technique. *J. Exp. Med.*, 157:884 .
- 91) **Grimm et al. (1983):** Predicta IFN- γ ELISA kit technique. *J. Exp. Med.*, 158:1356 .
- 92) **Grossberg, S.; Taylor, J. and Kushmaryov, VI (1989):** Interferon receptors and their role in IFN action. *Experientia*, 45:508-513 .
- 93) **Grosser, R. (1982):** Bayer A.G., Internal report.
- 94) **Gutterman, J.U. ; Herch , E.M. (1982):** Immunotherapy. In Holland, J.F. Frei, E. , Ed. *Cancer Medicine* , Philadelphia: Lea and Febiger, 1100-1132 .
- 95) **Hairston, N.G. (1973):** The dynamics of transmission. In: *Epidemiology and control of Schistosomiasis*. Ansari, N.

- (ed.), S. Karger, Basel and University park press, Baltimore, 302. (Cited by Abdel-Wahab, 1982).
- 96) **Harada, H.; Willison, K.; Sakakibara, J.; Miyanoto, M.; Fujita, T. and Taniguchi, T. (1991) :** Absence of type I interferon. System in EC cells: Transcription activation (IRF-1) and repressor (IRF-2) genes are developmentally regulated. *Cell*, **63**: 303-312.
- 97) **Harden, A.; Andrews, P. and Thomas, H. (1987):** Praziquantel: mode of action. *Bioch. Soc. Trans.*, **15**: 68-70 .
- 98) **Harnett, W. and Kusel. J.R. (1986):** Increased exposure of parasite antigens at surface of adult male *S.mansoni*, exposed to in vitro. *Parasitology*, **93**: 401-405 .
- 99) **Hart, P.H.; Vitti, G.E.; Burgess, D.R.; Whitty, G.A.; Piccole, D.S. and Hamilton, J.A. (1989):** Potential anti-inflammatory effects of interleukin-4: Suppression of human monocyte tumor necrosis factor, interleukin-1 and prostaglandin E2. *Proe. Natl. Acad. Sci. USA*, **86**: 3803-7 .
- 100) **Henderson, G.S.; Conary, J.T.; Summar, M. Colley, D.G. (1991):** In vivo molecular analysis of lymphokines involved in the murine immunoresponse during schistosoma mansoni infection. *J of Immunol.*, **147**: 442- 997.

- 101) **Henderson, G.S.; Lux, Mc Curley, A.N. and Colley, D.G. (1992):** In vivo molecular analysis of lymphokines involved in the murine immune response during *S.mansoni* infection. *J. Immunol.*, **148**, 2261-2269.
- 102) **Hoffman, D.B.; Lehman, J.R.; Scott, V.C.; Warren, K.S. and Webbe, G. (1980):** Control of schistosomiasis. *Am. J. Trop. Med. Hyg.*, **28**: 249-259.
- 103) **Howard, M. Farrar, J.; Hilfiker, M.; Johnson, B.; Takatsu, K.; Hamaoka, T and Paul W.E. (1982):** Identification of a T- cell derived B- cell growth factor distinct from TL-2. *J. Exp. Med.*, **155**:914.
- 104) **Hsu et al. (1985):** Predicta IFN- γ ELISA Kit technique. *Biochem.*, **24**:7959 .
- 105) **Hutadilok, N.; Thamarit, W.; Upatham, S. and Puenwongsa, P. (1983):** Liver collagen prolyl hydroxylase in *opisthorchis viverrini* infected hamsters, after praziquantel administration . *Mol. Biochem. Parasitol.*, **9**: 289-95 .
- 106) **Iarotski, L.S. and Davis, A. (1981):** The Schistosomiasis problem in the world : results of a W.H.O Questionnaire survey. *Bull. W.H.O.*, **59**:115 .
- 107) **Ijzermans, J.N.M. and Marquet, R.L. (1989):** Interferon Gamma : A review. *Immunobiol.* **179**: 456-473 .

- 108) Ismail, M.M.; Attia, M.M.; El-Badawy, A.A.; Farghaly, A.M.; Hussein, M.H and Metwally, A.M. (1994):**
Treatment of schistosomiasis with praziquantel among school children. J. Egypt. Soc. Parasitol., **24(3)**: 487-94 .
- 109) James, S.L.; Natoritz, P.C.; Farrar, W.L. and Leonard, E.J. (1984 b):** Macrophages as effector cells of protective immunity in murine schistosomiasis. Immun. **44**: 569-575 .
- 110) James, S.L. and Sher, A. (1990):** Cell mediated immune response to schistosomiasis. Current topics in Microbiology & Immunology, **155**:21-31 .
- 111) Jordan, P.; Christie, J.D. and Unrau, G.O. (1980):**
Schistosomiasis transmission with particular reference to possible ecological and biological methods of control. Acta Tropica, **37**,: 95-135 .
- 112) Jordan, P.; and Webbe, G. (1982):** Schistosomiasis, epidemiology, treatment and control. P. Jordan and G. Webbe (Eds.), William Heinemann Medical books LTD, London .
- 113) Kahrl J.H.; Muraguchi, A.; Gold smith, P.K; Fouci, A.S. (1985):** The direct effects of IL-1,IL-2, IFN- γ and B-cell growth factor and a B- cell differentiation factor on resting and activated human B cells .Cell Immunol., **96**:38-48 .

- 114) Kasahara, K.; Kobayashi, K.; Shikama, Y.; Yoreya, I. and Yoshida, T. (1989):** The role of monokines in granuloma formation in mice: The ability of interleukin -1 and tumor necrosis factor-alpha to induce lung granulomas Clin. Immunol. & Immunopathol., **51**:419-425 .
- 115) Kassim, O.O.; Dean, D.A.; Mangold, B.L. and von Lichtenberg, F. (1992):** Combined micro-auto radiographic and histopathologic analysis of the fate of challenge of *S. mansoni* schistosomula in mice immunized with irradiated cercariae. Am. J. Trop. Med. Hyg., **42**:231-237 .
- 116) Katz, N.; Rocha R.S.; and Chaves A. (1974):** Preliminary trials with praziquantel in human infection due to schistosoma mansoni. Bull W.H.O; **57**: 781-5
- 117) Katz N., (1980):** Current results in the clinical thenapy of *S.mansoni*. Rev.Inst.Med.Trop.Sao-Paulo, **22** (Suppl.4):8.
- 118) Katz, N. and Rocha, R.S. (1982):** Double blind clinical trials comparing praziquantel with oxamniquine in *S. mansoni*. Red. Inst. Med. Trop. Sao-Paulo. **24(5)** : 310-314
- 119) Keittivnti, B.; Keittiruti, A.; Rourke, O.T. and D. Agnes, T. (1984):** Assessment of *S. mansoni* with praziquantel in Cambodian refugees in holding centres in

Prackinburi province, Thailand. Trans. R. Soc. Trop. Med. Hyg., 78: 477:479 .

- 120) **Kelso, A and Cough N.M. (1988):** Expression of granulocyte macrophage ,colony stimulating factor, IFN , IL-3 and IL-4 is random in murine allo- reactive T- cell clones. Proc .Natl. Acad. Sci. USA., 85:9189 .
- 121) **Khalil, H.M.; Bebars, M.A.; El-Badawy, N.M.;Abdallah, H.M.; Khalil, N.M.; El-Zayyat, E.A. and El-Din Mohamed, M.S. (1995):** Effect of praziquantel treatment on hepatic pathology of *S. mansoni* in experimentally infected mice. J. Egypt. Soc. Parasitol., 25(1) : 269-77 .
- 122) **King etal. (1983):** Predicta IFN- γ ELISA kit technique .J. Immunol., 131: 315 .
- 123) **King, C.H. and Mahmoud, A.F. (1989):** Drugs five years later : praziquantel. Ann. Inter. Med., 110: 290-296 .
- 124) **King C.H., Wiper D.W, de stister Kv., Peteir P.A.S, Koech P., & Mahmoud A.A.F. (1989):** Dose finding studies for praziquantel therapy of *S.haematobium* in Coast Province, Kenya. Am. J. Trop. Med. Hyg., 40 : 507-13 .
- 125) **Kirchner, H. (1984):** Interferons: a group of multiple lymphokines. Springer Semin. Immunol., 7: 347-374 .

- 126) **Kirchner, H. (1989):** Viruses, blood transfusion and interferons. *Prog. Virol.* **4** :5-8 .
- 127) **Kobayashi, K.; Kasahara, K.; Shikama, Y.; Yoneyama, I.; Takahashi, T. and Yoshida, T. (1989):** Comparative studies on granuloma formation in vivo and in vitro. In: Yoshida, T. Torisu, M. eds. : Basic mechanisms of granulomatous inflammation. Amsterdam : Elsevier : 163-183 .
- 128) **Kupper, T.S. (1990):** The role of epidermal cytokines, I.N.; Oppenheim, J.J. and Shevach, E.M. (eds). Immunophysiology: The role of cells and cytokines in immunity and inflammation .Oxford University Press, New York, p. 285.
- 129) **Kushnaryo, V.V; Mac Donald, H. Le Mense, G. and Sedmark, J.(1988):** Quantitative analysis of mouse IFN- γ .B receptor mediated endocytosis and nuclear entry . *Cytobiol.*, **53**-147. .
- 130) **Le et al. (1983):** Predicta IL-2 ELISA kit technique J. *Immunol.*, **131**:2821 .
- 131) **Leopold, G.; Ungethüm, W.; Groll, E. et al. (1978):** Clinical pharmacology in normal volunteers of Praziquantel. A new drug against schistosomes and cestodes. *Eur. J. Clin. Pharmac.*, **14**:281-291.

- 132) **Linder, E. and Thors, C. (1992):** *S. mansoni* : praziquan
tel-induced tegumental lesion, exposed action of surface
spines and binding of actin depolymerizing factor,
gelsolin. *Parasitology*, **105**:71-79 .
- 133) **Lotze, M.T. (1992):** Human Cytokines. Aggarwal and
Gutterman Eds., Black Scientific Publishing, Chapter 5 .
- 134) **Lukacs, N.W. and Boros, D.L. (1993):** Lymphokine
regulation of granuloma formation in murine *S. mansoni*.
Clin. Immunol. Immunopathol., **68** (1) : 57-63 .
- 135) **MacDonald, G. (1965):** The dynamics of helminth
infections with special reference to schistosomes. *Trans. R.*
Soc. Trop. Med. Hyg., **59**:489-506 .
- 136) **MacDonald, N.J.; Kuhl, D.; Maquire, D.; Nat. D.;**
Gallant, P.; Goswamy, A. et al. (1990): Different
pathways mediate virus inducibility of human interferon
alpha-1 and interferon beta genes. *Cell*, **60**:767-779 .
- 137) **Mahmoud, A.A.F. (1987):** Praziquantel for the treatment
of helminthic infections. *Adv. Intern. Med.*, **32**:193-96 .
- 138) **Mahmoud, A.A.F. (1989):** Parasitic protozoa and
helminths: biological and immunological challenges.
Science, **240**:1015-1022 .
- 139) **Mandour, M.E.; El-Turabi, H.; Homeida, M.M.A.; El-**
Sadiq, T.; Ail, H.M.; Bennett, J.L.; Leahey, W.J.;

- Harron, D.W.G. (1990):** Pharmacokinetics of Praziquantel in healthy volunteers and patients with schistosomiasis. Trans. R. Soc. Trop. Med. Hyg., **84**, 389-393 .
- 140) McCelland, W.J.F. (1965):** The production of cercariae of *S. mansoni* and *S. haematobium* and methods for estimating the numbers of cercariae in suspensions. Bull, WHO, **33**:276 .
- 141) McMahan, J.E. (1981):** A note on drug trials in schistosomiasis. Trans. R. Soc. Trop. Med. Hyg., **75**(4):597 .
- 142) Medley, G.F. and Anderson, R.M. (1985):** Density-dependent fecundity in *S. mansoni* infection in man. Trans. R. Soc. Trop. Med. Hyg., **79**:532-534 .
- 143) Mehlhorn, H.; Becker, B.; Andrews, P.; Thomas, H. and Frenkel, J.K. (1983):** In vivo and in vitro experiments on the effects of praziquantel on *S. mansoni*. Helminthol. Abst. **A52 (8)**:464 .
- 144) Meister, A.; Uze, G. and Mogensen, K. (1986):** Biological activities and receptor binding of two human recombinant interferons and their hybrids. J. Gen. Virol. **67**:1633-1643 .
- 145) Metwally, A.A.; Botros, S.S.; Roushdy, M.Z. and Khayal, M.T. (1984):** Prophylactic activity of praziquantel.

- uantel in experimental *S. mansoni*. J. Egypt. Med. Ass., **67** (Suppl 3): 35-46 .
- 146) Metawilly A.A. (1989):** Pharmacokinetics of praziquantel in schistosomal patients. Egypt. J. Bilh., **11**:133-43 .
- 147) Michelson, E.H. (1986):** Preliminary observation on a heamolymph factor influencing the infectivity of *S.mansoni* miracidia. Acta Tropica, **43**:63-68 .
- 148) Miller, P. and Wilson, R.A. (1978):** Migration of schistosomula of *S. mansoni* from skin to lungs. Parasitology, **77**:281-302 .
- 149) Miller, P. and Wilson, R.A. (1980):** Migration of the schistosomula of *S. mansoni* from lungs to the hepatic portal system. Parasitology, **80**:267-288 .
- 150) Milton, J.S. and Tsokos, J.O. (1983) :** Statistical methods in the Biological and Health Sciences. Int. stud. Ed.
- 151) Modha, J.; Lambertucci, J.R.; Doenhoff, M.J. and McLaren, D.T. (1990):** Immune dependence of schistosomicidal chemotherapy : an ultrastructural study of *S.mansoni* adult worms exposed to praziquantel and immune serum in vivo. Parasit. Immunol., **12**(3): 321-34 .
- 152) Mohamed Ali, A.; Doebling - Schweidtfegen, E. et al. (1991):** Ultrasonographical investigation of perportal fibrosis, in children with schistosoma mansoni infection : reversibility of morbidity seven months after treatment with praziquantel. Am. J. Trop. Med. Hyg., **44**:444-51 .

- 152) Moore; F.D. Jr. Schoofs; D.D. Rodrick; M. and Eberlein T.J. (1991):** The systemic complement activation caused by IL-2 lymphokine activated killer cell therapy of cancer causes minimal systemic neutrophil activation. *Int. J. Cancer*, **49**(4): 504.
- 153) Morgan et al. (1976):** Predicta IL-2 ELISA technique . *Science*, **193**:1007 .
- 154) Morven Roberts; Anthony E. Butterworth; Gachuhi; Kimani; Timothy Kamau; Anthony J.C. Fulford; David W. Dunne; John H. Ouma and Robert F. Sturrock (1993):** Immunity after treatment of human Schistosomiasis : Association between cellular responses and resistance to reinfection. *Infection and Immunity*, p. 4984-4993 .
- 155) Mosmann, T.R. and Coffman, R.L. (1989):** TH1 and TH2 cells : Different patterns of lymphokine secretion, lead to different functional properties. *Ann. Rev. Immunol.*, **7**:145 .
- 156) Mosmann and Coffman (1989):** Predicta IL-2 ELISA kit technique. *Ann. Rev. Immunol.*, **7**:150 .
- 157) Mott, K.E. (1987):** Epidemiological considerations for development of a schistosome vaccine. *Acta Tropica*, **44** (Suppl. 12) : 13-20 .

- 158) **Murry, H.W. (1988):** Interferon gamma, the activated macrophage and host defense against microbial challenge. *Ann. Intern. Med.* **108** : 595-608 .
- 159) **Nash, T.E.; Cheever, A.W.; Ottesen, E.A. and Cook, J.A. (1982):** Schistosome infections in humans-prospectives and recent finding. *Annals Int. Med.*, **97**, 740-754 .
- 160) **Nathan et al. (1983):** Predicta IL-2 ELISA kit technique. *J. Exp. Med.*, **158**:670 .
- 161) **Ohmae, H.; Tanaka, M.; Hyashi, M.; Matsugaki, Y.; Kuosaki, Y.; Blas, B.L.; Sy, O.S.; Irie, Y. and Yasuraoka, K. (1992):** Improvement of ultrasonographic and serologic changes in *S. mansoni* infected patients, after treatment with praziquantel. *Am. J. Trop. Med. Hyg.*, **46**(1):99-104 .
- 162) **Oppenheim, J.J; Ruscetti, F.W. and Connie, F. (1991):** Cytokines, I.N.; Stites D.P. and Terr A1 (eds) *Basic and clinical Immunology*, 7th edition. Appleton and Lange, London, Sydney, Toronto, Mexico, New Delhi, Chapter 7, p. 78.
- 163) **Paucker et al. (1962):** Predicta IL-2 ELISA kit technique . *Virology*, **17**:324 .
- 164) **Paul, W.E.; Mizuguchi, J.; Brown, M. (1984):** Regulation of B lymphocyte activation, proliferation and

imuno globulin. Secretion cell. **99**, 7-13 Kehrl, J.H.
Muraguchi & Goldsmith, P.K. Fouci, A.S. (1985) the
direct effects of IL-1, IL-2, IFN-alpha, IFN-B, B-cell
growth factor and a B- cell differentiation factor on resting
and activated human B- cells. *Cell Immunol* **96**, 38-48 .

165) Pax, R.; Bennett, J.L. and Petter, R.A. (1978): A
benzodiazepine derivative and praziquantel effects on
musculature of *S. mansoni*. *Naunyn. Schmiedeberg's Arch.*
Pharmacol. **304**: 309-15 .

166) Pearce, E.J.; Basch, P.F. and Sher, A. (1986a): Evidence
that the reduced surface antigenicity of developing
S.mansoni schistosomula is due to antigen shedding rather
than host molecule acquisition. *Parasite Immunol.*, **8**:79-94

167) Pearce, E.J.; and Sher, A. (1987): Mechanisms of
immune evasion in schistosomiasis. *Contributions to*
microbiology and immunology, **8**:219-232 (Abstract) .

168) Pearce, E.J.; Caspar, P.; Grzych, J.M.; Lewis, F.A. and
Sher, A. (1991): Down regulation of TH1 cyto kine
production accompanies induction of TH2 responses by a
parasitic helminth: *S. mansoni* . *J. of experimental*
medicine, **3**:159-166 .

- 169) **Pesigan, T. P.; Farooq, M.; Hairston, N.G. et al. (1958):**
Studies on *S. gaponicum* infection in the Phillipines.
Preliminary control experiments. Bull. WHO, **19:223** .
- 170) **Pestka et al. (1987):** Predicta IL-2 ELISA kit technique .
Ann. Rev. Biochem., **56:727** .
- 171) **Pestka, S.; Langen, J.A.; Loon, K.C. and Samuel, C.E.**
(1987): Interferons and their actions. Ann. Rev. Biochem.
56:227-277
- 172) **Piper, K.P.; Mott, R.F.; Hockely, D.J. and Maclaren,**
D.J. (1991): *S. mansoni* larval damage and role of effector
cell in the synergy between vaccine immunity and
praziquantel treatment. Parasitology, **107:207-224** .
- 173) **Pelligrini and schindler (1993):** Predicta IL-2 ELISA kit
technique. Trends in Biol. Sci., **18:338** .
- 174) **Pons, H.A.; Morgan, S.S.; Hutchinson, M.L. et al.**
(1989): Resistance to reinfection in experimental murine
schistosomiasis : role of portohepatic haemodynamics.
Am. J. Trop. Med. Hyg., **41:189-197** .
- 175) **Product information Schering (1989):** Information on
Schering products .
- 176) **Protzman, W.P.; Minnicozzi, M.; Jacobs, S.L.**
Suaprenaut, D.I., Schwartz, J., et al. (1985): Immuno
radiometric assay of a recombinant human alpha-2
interferon. J. Clin. Microbiol. **22:596-599** .

- 177) **Ralph, P.; Nakoin Z.I. and Rennick, D. (1988):** Role of interleukin-2, IL-4 and alpha, B interferon in stimulating macrophage-antibody dependent tumoricidal activity. *J. Exp . Med.* **167**-712 .
- 178) **Renz H.K Jujo, K.L. Bradley. (1992):** J. Domenico, E.W. Gelfand and D Y.M. Laung. Enhanced IL-4 production and IL-4 receptor expression in atopic dermatitis and their modulation by interferon Gamma. *J. Invest. Dermatol*, **99** .
- 179) **Robb et al. (1981):** Predicta IL-2 ELISA kit technique . *Mol. Immunol.*, **8**: 1087 .
- 180) **Roberts, R.M. (1989):** A novel group of interferons associated with the early ovine and bovine embryo. *J. Interferon Res.* **9**: 373-378 .
- 181) **Roberts, M.; Butterworth, A.E.; Kimani, G.; Kamau,T; Fulford, A.J.; Dunne, D.W.; Ouma, J.H. and Sturrock, R.F. (1993):** Immunity after treatment of human schistosomiasis : association between cellular responses and resistance to reinfection. *Infect. Immun.*, **61** (12): 4984-93 .
- 182) **Rocklin, R.E.; Tracy J.W. and El Kholy (1981):** Activation of antigen-specific suppressor cells in human schistosomiasis mansoni by fractions of soluble egg antigens nonadherent to Con A sepharose. *J. Immunol.* **23**:4

- 183) Romagnani and Maggi (1994):** Predicta IL-2 ELISA kit technique. *Curr. Opin. Immunol.*, **4**:616 .
- 184) Roper, R.L.; Conard, D.H., Brown, D.IM.; Worner G.L. and Phipps, R.P. (1990):** *J. Immunology*, p. **11**: 56:68 .
- 185) Rosenberg et al. (1985):** Predicta IL-2 ELISA kit technique. *N.E. Journ. Med.*, **313**:1485 .
- 186) Rosenberg, S.;A. Latzen, M. Muul; L. Change; A. Avis F. Leitman; S. Linehan; W. Robertson; C. Lee; R. Rubin; J. Seipp; C. Simpson. and White, D. (1987):** A progress report on the treatment of 157 patients with advanced cancer, using lymphokine, activated killer cells, and IL-2 or high dose IL-2. *N. Engl. J. Med.*, **316**:889 .
- 187) Ruenwongsa, P.; Hutadilok, N. and Yuthuogy, C. (1983):** Stimulation of Ca⁺⁺ uptake in the human liver fluke.; *Opisthorchis viverrini* by praziquantel . *Life Sci.*, **32**:2529-34 .
- 188) Ruiz - Tiben, E.; Hillyer, G.V., Knight, W.B. et al. (1979):** Intensity of infection with *S. mansoni* : its relationship to the sensitivity and specificity of serologic tests. *Am. J. Trop. Med. Hyg.*, **28**:230-236 .
- 189) Ruscetti et al. (1977):** Predicta IL-2 kit technique. *J. Immunol.*, **119**:131 .

- 190) Sabah, A.A; Fletcher, C.; Webbe, G. and Doenhoff, J.M.(1985): *S. mansoni* : chemotherapy of infection of different eggs. *Experimental Proces.*, **61** : 294 - 303.
- 191) Sato, I.Y., Kobayashi, K.; Kasama, T. and Kaga, S. (1990): Regulation of mycobacterium (BCG) and foreign body granulomas in mice by the Boe gene. *Infect. Immuni.*, **58**, 1210-1216.
- 192) Sato, I.Y.; Kobayashi, K.; Yamagata, N. and Shikama,Y.(1991): Modulation of granuloma formation in vitro by endogenous mediators. *Immuno. Pharmacology*, **21**:73-82.
- 193) Schreiber et. al.; (1985): Predicta IL-2 ELISA technique. *Lymphokines*, **11**:87.
- 194) Sechler, J.M.G., Malech,H.L.; White, C.J. and Gallin, J.I. (1988): Recombinant human interferon gamma reconstitutes defective phagocytic function in patient with chronic granulomatous disease of childhood. *Proc. Nat. Acad. Scie. USA.*, **85**: 4874-4878.
- 195) Seubert, J.; Pohlke, R.; Loebich,F.(1977): Synthesis and properties of praziquantel, a novel broad spectrum antihelminthic with excellent activity against schistosomiasis and cestodes. *Experientia*, **33**-1036.

- 196) **Shaker, Z.A.; Hassanein, H. I.; Kamel, M.M.; El-Bahairy, N.M. et. al., (1987):** Effect of PZQ on certain immune responses of schistosomal Egyptian patients : changes of specific immunoglobulins. *Parasitol. Res.*, **73**: 328-333.
- 197) **Shao, B.R.; Xiao , S.H. ; Wu. H.M. and Zhan, C.Q. (1981):** Heart rhythm disturbance in rabbits induced by Pyquilon and the drugs for its treatment and prevention. *Yao-Hsueh-Pao. Jun.*, **16** (6) : 407-10 (Abstract).
- 198) **Sharaf El- Din,S.; Hussein,L.; Omran,N.; Mourad, M.; Omran, S.; Abdel-Hady, S. and Salem,F. (1990):** Clinical evaluation of the adverse effects of the recent oral antibilharzial drujs in children in Egypt. *Med. J. Cairo Unive.*, **58**:212-222.
- 199) **Shaw, M.K. and Erasmus, D.A. (1983):** S. mansoni : the effect of subcurative dose of PZQ on the ultrastructure of worms in vivo. *Z. Parasitnek.*, **69**: 73 -90.
- 200) **Shaw , M.K. (1990):** S. mansoni : Stage depentent damage after in vivo treatment with praziquantel. *Paraistol.*, **100**: 65-72.
- 201) **Sher, A. Coffman, R.L.; Hieny, S. and Scott, P. (1990):** IL-5 is required for the blood and tissue eosinophilia.

Abstract of international conference on schistosomiasis
672-79.

- 202) **Sher, A. (1993):** Immunoregulatory and immunopathogenic role of TH2 cytokines in murine schistosomiasis . Abstract of international conference on schistosomiasis 672-79.
- 203) **Shikama, Y.; Kobayashi, K. and Kasahara (1989):** Granuloma formation by artificial microparticles in vitro. Am.J. Pathol., 134: 1189-1199.
- 204) **Smith,J.; Urba, W.; Steis, R. et. al., (1990):** IL-1alpha results of a phase 1 toxicity and Immunomodulatory trial. Au. Sac. Clin. Oncol., 9:717.
- 205) **Smithers, S.R. ; McLaren, D.J. and Ramalho-Pinto, F.J. (1977):** Immunity to schistosomes the target. Am. J. Trop. Med. Hyg., 26:6 .
- 206) **Smithers, S.R. and Doenhoff, M.J. (1982):** Schistosomiasis in: Immunology of parasitic diseases. Blackwell, Oxford.
- 207) **Soffier et al. (1992):** Predicta IL-2 ELISA kit technique . Blood, 79:517.
- 208) **Sonnabend, J.A. (1967):** Interferons: production of interferon, characters and purification. Nature (London) 203: 496 (25-230).

- 209) **Stadecker, M.J. and Colley, D.G. (1992):** The immunobiology of schistosome egg granuloma. *Parasitology Today*, **8**: 218-220.
- 210) **Standiford, T.J.; Strieter, R.M.; Chensue, S.E.; Westwick, J. Kasahara,K. and Kasken (1990) :** IL-4 inhibits the expression of IL-8 from stimulated human monocytes, *J. Immunol.*, **145**-1435.
- 211) **Steeg et al., (1982):** Predicta IFN- G ELISA kit technique . *J. Exp. Med.*, **156**: 1780.
- 212) **Steiner, K. and Garbe, A. (1976):** The fate of PZQ in the organism. II. Distribution in rats. *Eur. J. Drug Metab. Pharmacok.*, **2**:97-100.
- 213) **Stelma, F.F.; Toual. I.; Sow, S.; Kongs, A. ; Niang,M. ; Polman, K. ; Deelder, A. M. and Gryseels, B. (1995):** Efficacy and side effects of praziquantel in an epidemic focus of *S. mansoni*. *Am. J. Trop. Med. Hyg.*, **53**(2): 167-70 .
- 214) **Stephen, W.; Chensue Kelly Warmington; Jeffry Ruth; Pamela Lincoln; Mei-chen Kuo, and Steven L. Kunkel (1994):** Cytokine responses during mycobacterial and schistosomal antigen-induced pulmonary granuloma formation. Production of Th 1 and Th 2 cytokines and

relative contribution of tumor necrosis factor. Am. J. Path., Vol. 145, No. 5.

- 215) **Stewart II, W.E.; DeClerque, E. and DeSomer, P. (1974):** Stabilization of IFNs by defensive reversible denaturation. Nature (London) 249: 400-461.
- 216) **Strickaland, G.T. (1986):** Schistosomiasis. In clinical medicine, Spittell, J.A. (ed). Harper & Row, Philadelphia , Vol. 3 : 1-23.
- 217) **Stuart P.M.; Zlatnik, A. and Woodward, J.C. (1988) :** Induction of class I and Class II MHC antigen expression on murine bone marrow derived macrophages, by IL-4 B-cell stimulatory factor I. J. Immunol., 140:1542.
- 218) **Sturrock, R.F. (1987):** Biology and ecology of human schistosomes in Mahmoud, A.A.F.(ed), Schistosomiasis, Bailliere's Clin. Trop. Med. Comm. Dis., 2 : 240-266.
- 219) **Sukwa, T.Y. , Bushara M.K. and Wurapa, F.K. (1981):** Reduction in prevalence intensity of infection and morbidity due to schistosoma mansoni infection in a community following ttt with praziquantel. J. Trop. Med. Hyg., 90-205-11.

- 220) **Talla, I. et al. (1990):** Outbreak of intestinal schistosomiasis in the Senegal river Basin. *Ann. Soc. Belg. Med. Trop.*, **70**: 173-180. (cited by Chefras, 1991).
- 221) **Talmadge, J.E.; Schneider, M.; Keller, J.; Ruscetti, F.; Longo. D.; Pennington, R.; Bowersox, O, and Tribbls, (1989):** Myelostimulatory activity of recombinant human IL-2 in mice. *Blood*, **73** (6): 1458.
- 222) **Taniguchi, T. (1988):** Regulation of cytokine expression. *Am. Rev. Immunol.* **6**: 439-464.
- 223) **Tevelde, A.A.; Huijbens, R.J.; Heji K.; De Vries J.E. and Figdor, G.G. (1990):** IL-4 inhibits secretion of IL-1 beta tumor necrosis factor alpha and IL-6 by human monocytes **76**(7): 1392 .
- 224) **Thomas, H. and Gonnert, R. (1977):** The efficacy of praziquantel against cestodes in animals. *Zeitschrift fur Parasitendunke*, **52**: 117-127.
- 225) **Tovey, M.G. (1988):** The expression of cytokines in the organs of human individuals. Role in homeostasis. *J. Biological Regul. of homestatic agents*, **2** , 87-92.
- 226) **Trinchieri et al. (1985):** Predicta IFN-G ELISA kit technique. *Immunol., Today*, **6** : 131 .
- 227) **Tweardy, D.J.; Osman, G.S.; El-Kholy , A. and Ellner, J.J. (1987):** Failure of immunosuppressive mechanisms

in human schistosoma mansoni infection with hepatosplenomegaly. J. Clin. Microbiol., **25**: 768 .

- 228) Vignali, D.A.A.; Q.D., Bickle ; Taylor, M.G. (1989):** Immunity to Schistosoma mansoni in vivo : contradiction or clarification? Immunol . Today, **10**: 410-416 .
- 229) Von Lichtenberg, F. (1990):** Experimental approaches to human schistosomiasis. Am. J. Trop. Med. Hyg., **26**: 79.
- 230) Wahls, M.; McCartney-Francis, N.; Hunt, A.; Smith, P.D.; Wahl, L. M. and Katona, I.M. (1988):** Monocyte IL-2 receptor gene expression and IL-2 augmentation of microbicidal activity. J. Immunol., **139**: 1342.
- 231) Warren, K.S.; Domingo E.O. and Cowan , R. (1967) :** Granuloma formation around schistosome eggs as a manifestation of delayed hypersensitivity. Am. J. Pathol., **51**: 735-745.
- 232) Warren, K.S.; Pelly, R.P. and Mahmoud, A.A.F. (1977):** Immunity and immunopathology following reinfection of mice cured from chronic S. mansoni. Am. J. Trop. Med. Hyg., **26**: 957-962.
- 233) Warren, K.S. (1987):** The secret of the immunopathogenesis of schistosomiasis: In vivo models. Immunological Rev., **61**: 189-207.

- 234) **Watt, G.; White, N.J.; Padre, L.; Ritter, W.; Fernando, M.T.; Ranoa C.P. and Laughlin, L.W. (1988):** Praziquantel pharmacokinetics and side effects in *Schistosoma Japonicum* infected patients with liver disease. *J.Infect. Dis.*, Vol. **157**, No. 3 pp. 530-535.
- 235) **Watt G.; Padre. L.P.; Tuazon, M.; Wetherspoon, A. and Adopon, B. (1991):** Hepatic parenchyma dysfunction in *S. mansoni* infection. *J. Infect. Dis.*, **164**(6) : 1186-92.
- 236) **Webbe, G. and James, C. (1977):** A comparison of the susceptibility to praziquantel of *S. mansoni* and *S. Haemato -bium* in hamsters. *Z. Parasitenk*, **52** : 169-177.
- 237) **Weber, H.; Valenzuela, D. and Weissman, C. (1987) :** Single amino acid changes that render human IFN biologically active on mouse cells. *E M B O J.*, **6** : 591-598.
- 238) **Wegner, D.H. (1984):** The profile of the treatmocidal compound PZQ. *Arzneimittelforschung*, **34**:1132-6 (abstract).
- 239) **Weiss, L.; Haeffiner-Cavaillon, N.; Laude, M.; Cavaillon , J.M. and Kazatchikine. M.D. (1989):** Human T -cells and interleukin 1 induced by lipopolysaccharide in serum-free cultures of autologus monocytes. *Eur. J. Immunol.*, **19**: 1347-1350 .

- 240) **Weissman, C. and Weber, H. (1986):** The interferon genes. *Prog. Nucleic Acid Res. Mol. Biol.*, **33**: 251 -300.
- 241) **Wheelock (1965):** Predicta IL-2 ELISA technique. *Science*, **149**:310.
- 242) **Wills, R.J. (1990):** Clinical pharmacokinetics of Interferons. *Clin. Pharmacokin.*, **19** (5), 391-399.
- 243) **Wilson, R.A. and Coulson, P.S. (1986):** *S. mansoni* : dynamics of migration through the vascular system of mice. *Parasitology*, **92**: 83-100 .
- 244) **Wu, C.H.; Giambrone, M.A.; Howard, D.J.; Rojkind, M. and Wu, G.Y. (1982):** The nature of collagen in hepatic fibrosis in advanced murine schistosomiasis. *Hepatology*, **2**:366-371.
- 245) **Xiao, S.H.; Freidman, P.A.; Catto, B.A. and Webster, T. (1984):** PZQ- induced vesicle formation in the tegument of male *S.mansoni* is calcium dependent. *J. Parasitol.*, **70**:177-179 .
- 246) **Zoon, K.C. (1987):** Human Interferon:structure and function. *Interferon*, **9**: 1-12 .
- 247) **Zwingenberger, K., E.; Irschick, J.G.; Siqueira Vergetti, A.R.; Correia Dacal, R.; Janssen-Rosseck. ;**

Bienzle, C.; Huber, H. and Feldmeier, H. (1989): Release of interleukin-2 and Gamma interferon by peripheral mononuclear cells in human schistosoma mansoni infection, normalises after chemotherapy. Scand. J. Immunol., **30**:463-471 .

248) Zwingenberger, G.; Harms, U.; Poggensee A.; Steiner, K.; Muller, O. and Feldmeier, H. (1990): Reinfection in human schistosomiasis mansoni : a prospective field study 18 months after praziquantel therapy. Ann. Trop. Med. Parasitol., **84**: 457-465 .

249) Zwingenberger, K.; Ritcher, J.; Vergetti J.G. and Feldemeier, H. (1990): PZQ in the treatment of hepatosplenic schistosomiasis : biochemical disease markers indicate deceleration of fibrogenesis and diminution of portal flow obstruction. Trans. R. Soc. Trop. Med. Hyg., **84**:252-256.

250) Zwingenberger, K.; Holmann, A.; DeBrito, M.C and Ritter, M. (1991): Impaired balance of IL-4 and IFN-G production in infections with S.mansoni and intestinal nematodes. Scand. J. Immunol., **34 (2)**: 243-251 .